AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06660186 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wire Cerclage
Description: The surgeon will close the sternum (breastbone) using Wire Cerclage. Wire Cerclage consists of stainless steel wires used to hold the two halves of your sternum together.
Study NCT06659406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 will be given once daily, 200mg for the period of 3 months
Study NCT06662175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine
Description: Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
Study NCT06662175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperbaric bupivacaine and dexmedetomidine
Description: Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
Study NCT06659497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based patient education
Description: The web-based training, which will provide the following information about the IUI treatment process, will last a total of 60 minutes.~MODULE 1: General Information About Fertility MODULE 2: Diagnostic and Therapeutic Methods in Infertility / Insemination Treatment MODULE 3: Drugs Used in Insemination Treatment and Their Application MODULE 4: Things to Consider After Insemination
Study NCT06660797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group1: A matching gutta-percha master cones will be used in up and down motion 2mm amplitude at a frequency of 100 strokes during approximately 1 min in each prepared canal.
Description: The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by matching gutta percha master cone , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
Study NCT06660797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group2: XP-endo Finisher activation: The XP-endo Finisher instrument will be used in continuous rotation for 1 mintute
Description: The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by XP-endo Finisher used in continuous rotation for 1 minute , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
Study NCT06660797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3:EasyClean system activation : EC instrument coupled to the countrangle handpiece and operated with a micromotor at approximately 20,000 rotations per minute in continuous rotation.
Description: after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by EasyClean system activation , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
Study NCT06600282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: Pharmacokinetic study under fasting conditions
Study NCT06600282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Pharmacokinetic study under fasting conditions
Study NCT06661629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve stimulation
Description: The intervention is testing the effect of bilateral genioglossus muscle stimulation on upper airway collapsibility during drug-induced sleep endoscopy in patients implanted with the Inspire hypoglossal nerve stimulator
Study NCT06658626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]Enlicitide chloride
Description: IV Injection
Study NCT06661785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: large orbital floor fracture
Description: Twenty two patients with large orbital floor fracture will be reconstructed with interlocking polyetheretherketone patient-specific implant
Study NCT06660992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858, tablet
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
Study NCT06660992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo comparator of study
Study NCT06662006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI,5-fu,LV, benmelstobart, anlotinib
Description: liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
Study NCT05435859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Tasks
Description: Listen to 25-minutes of speech sounds in English.
Study NCT06625138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Latex Band
Description: Hemorrhoid banding with latex band
Study NCT06625138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Latex Band
Description: Hemorrhoid banding with non-latex bands
Study NCT04720755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Extracorporeal Shock Wave Therapy
Description: Twice-weekly treatments for 6 weeks, of 0.2mL/mm\^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
Study NCT06292637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Faith Fellowship to Improve Thy Health (CB-FAITH)
Description: CB-FAITH is a behavioral depression intervention set inside a cognitive behavioral framework, and Afrocentric paradigm and informed by faith-based principles, designed to treat major depressive disorder among African American adults. The 13-treatment modules focus on increasing knowledge of depression and healthy coping behaviors. It is designed to be co-delivered by licensed mental health clinicians and pastors at churches.
Study NCT06459999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine and circulating blood biomarkers
Description: Urine and circulating blood biomarkers in all cohorts
Study NCT06180629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music conset
Description: The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
Study NCT06180629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal treatment routine
Description: normal treatment routine
Study NCT06034873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol injection and fentanyl
Description: The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
Study NCT06034873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
Study NCT05035953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Edaravone Dexborneol matching injection, addition to thrombolysis
Study NCT05953597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
Study NCT04742803 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Straberi Epistamp Microneedling Treatment
Description: The patient's entire face will be treated with the Straberi Epistamp needling device.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm
Study NCT04927156 — intervention group
Intervention type: DEVICE
Intervention: BALT medical devices
Description: Includes, but is not limited to, the following:~* Access devices~* Aneurysm treatment devices~* Ischemic Stroke and peripheral occlusive diseases treatment devices~* Arterio-Venous Malformations/fistulas treatment devices
Study NCT05446766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided Exposure-based Digital Intervention for Health Anxiety
Description: An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days.
Study NCT06106061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Decompression + FFX®
Description: Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression associated with the use of FFX® implant
Study NCT06106061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression alone
Description: Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression alone
Study NCT06520462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Description: The physicians will decide the specific methods of pharmacopuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
Study NCT06520462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The physicians will decide the specific methods of acupuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
Study NCT04566900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
Study NCT04566900 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
Study NCT06035172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided imagery
Description: The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
Study NCT06035172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music recital
Description: It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
Study NCT05898620 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGN-401
Description: NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Receive aerobic exercise encouragement
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Receive aerobic exercise encouragement
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Consume high protein snack/meal/shake
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Receive nutritional consultation and guidelines
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Receive nutritional consultation and guidelines
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05056805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Complete strengthening exercise
Study NCT05749224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Helkimo Index
Description: Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
Study NCT05372653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406
Description: 0.3% or 1% ointment, topical, twice daily, for 52 weeks
Study NCT05036018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACURATE neo2
Description: The ACURATE neo2 valve will be implanted using a two-step mechanism during transfemoral transcatheter aortic valve implantation (TAVI). Balloon predilatation will be recommended in the ACURATE neo 2 valve group.
Study NCT05036018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimalist approach
Description: Isolated local anesthesia. Central venous lines, additional arterial lines for blood pressure monitoring, and urinary catheters will be avoided. Insertion of temporary pacemakers is optional and should be avoided whenever possible, and peri-procedural pacing can then be performed on the left ventricular wire. Presence of an anesthesiologist is optional. Patients will be directly transferred to the cardiology ward after the procedure, which can be postponed in case of complications.
Study NCT05667545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptide
Description: it is about synthetic protein acting on tooth structure help information apatite crystals
Study NCT04646304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Objective Feedback (Motion Capture)
Description: Participants assigned to the objective feedback group will be given a report after completing Set 1 and Set 2. This report will outline their performance for each significant factor (identified in Phase 1) relative to a target interval, derived from the staff surgeon group average (± one standard deviation). Participants assigned to the objective feedback group will then be able to repeat the tasks knowing which variables to improve.
Study NCT05875727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: One dose of 20vPnC will be administered intramuscularly.
Study NCT05143749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video tutorial
Description: get video tutorial
Study NCT05969899 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFIRI+Bevacizumab
Description: irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
Study NCT05211232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
Study NCT05211232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
Study NCT06263907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate gangalion block
Description: The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block
Study NCT04244981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate, Human
Description: A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
Study NCT04244981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: When APTT is prolonged (> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
Study NCT04812028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
Study NCT06327373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Supplemental oxygen by oxygen concentrator
Study NCT06327373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Room air without oxygen concentrator
Study NCT03631771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Iohexol administered intravascularly
Study NCT03631771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: Iodixanol administered intravascularly
Study NCT04729114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL-02 injection
Description: abiraterone decanoate for intramuscular injection
Study NCT04729114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Oral dose